

Johnson & Johnson and Subsidiaries
Reconciliation of Non-GAAP Financial Measures

<i>(Dollars in Millions Except Per Share Data)</i>	First Quarter		% Incr. / (Decr.)
	2013	2012	
Earnings before provision for taxes on income - as reported	\$ 4,261	5,045	(15.5) %
Litigation expenses	529	-	
Synthes integration/transaction costs and currency related	258	(117)	
In-process research and development	64	-	
Other	(42)	-	
Earnings before provision for taxes on income - as adjusted	<u>\$ 5,070</u>	<u>4,928</u>	<u>2.9 %</u>
Net Earnings - as reported	\$ 3,497	3,910	(10.6) %
Litigation expenses	391	-	
Synthes integration/transaction costs and currency related	183	(106)	
In-process research and development	42	-	
Other	(6)	-	
Net Earnings - as adjusted	<u>\$ 4,107</u>	<u>3,804</u>	<u>8.0 %</u>
Diluted Net Earnings per share - as reported	\$ 1.22	1.41	(13.5) %
Litigation expenses	0.14	-	
Synthes integration/transaction costs and currency related	0.06	(0.04)	
In-process research and development	0.02	-	
Other	-	-	
Diluted Net Earnings per share - as adjusted	<u>\$ 1.44</u>	<u>1.37</u>	<u>5.1 %</u>

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.